Zoetis Inc. (NYSE: ZTS), a leading animal health company, saw its shares tumble 5.09% in pre-market trading on Tuesday following the release of its third-quarter 2025 financial results. The sharp decline comes as the company reported mixed results, with revenue falling short of analyst expectations despite an earnings beat.

For the third quarter, Zoetis reported revenue of $2.400 billion, marking a slight increase of 0.50% compared to the same period last year. However, this figure missed the analyst consensus estimate of $2.421 billion. The revenue shortfall appears to be the primary driver behind the stock's pre-market plunge, as investors react to the company's inability to meet top-line growth expectations.

On a more positive note, Zoetis posted adjusted earnings per share of $1.70, surpassing the analyst consensus estimate of $1.62 by 4.81%. This represents a 7.59% increase from the $1.58 per share reported in the same quarter of the previous year. Despite this earnings beat, the market seems more focused on the revenue miss, highlighting the importance investors place on top-line growth in the current economic environment. The company also provided its full-year outlook, projecting revenue between $9,400 million and $9,475 million, with adjusted diluted EPS expected to fall between $6.30 and $6.40.